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The proliferation and in vitro cytolytic activity of interleukin-2 (IL-2)-activated and anti-CD3+IL-2-stimulated marrow mononuclear cells (MMC) and peripheral blood mononuclear cells (PBMC) were studied. Samples from 8 normal donors, 15 patients with acute lymphoblastic leukemia (ALL), and 7 patients with non-Hodgkin's lymphoma (NHL) in remission were cultured in IL-2 (100 U/mL) or IL-2 (100 UlmL) plus anti-CD3 (10 ng/mL). MMC as well as PBMC samples demonstrated significant synergy between IL-2 and anti-CD3 in the promotion of proliferation as measured by 3H thymidine incorporation on day 5 (P c .001) or fold increase in cell number on day 14. Cryopreserved marrow specimens had equally rapid proliferation as fresh MMC when cultured in the presence of anti-CDB+IL-2. Anti-CD3 concentrations of 3,11, 33, and 100 ng/mL augmented proliferation similarily in the presence of IL-2 (0.1 t o 100 U/mL). Mean fold increases in cell number of both marrow-and blood-derived cultures after 14 days were significantly higher for anti-CD3+IL-2-stimulated cultures compared with cultures stimulated with IL-2 only (50-t o 200-fold increase in cell number; P = .Ol). Comparison of remission MMC and PBMC from ALL and NHL patients with normal controls showed equivalent growth rates of activated cultures at 7,14, and 21 days. Marrow purging with immunotoxin anti-CD19 pokeweed antiviral protein plus 4HC had no significant effect on proliferation of anti-CD3+IL-2-stimulated MMC cultures in patients with ALL. Cytolytic
OST-BONE marrow transplantation (BMT) relapse is
P the major problem after autologous BMTl-' of highrisk patients with B-lineage acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL). Patients receiving allogeneic marrow transplants for B-lineage malignancy have less risk of r e l a p~e~.~ because of antineoplastic effects of acute and chronic graft-versus-host disease (GVHD). We have reported that, following allogeneic BMT for ALL, the presence of GVHD was associated with a significantly reduced risk of relapse compared to patients without GVHD. 8 This reduction in relapse associated with GVHD may be caused by the possibility of a graft-versus-leukemia e f f e~t .~ Attempts to stimulate graft versus leukemia in experimental animals against B-lineage malignancy have MMC cultures was assessed in 51Cr release assays using K562 (natural killer ([NKI-sensitive), Daudi (Burkitt's lymphoma-, NK-resistant), and Nalm-6 (ALL-, lymphokine-activated killer [LAKI-resistant) cell lines and cryopreserved ALL blasts. Cytolytic activity on a per-cell basis (percent cytotoxicity at an effector:target ratio of 30: 1) was similar in IL-2-activated PBMC-and MMC-derived cultures from ALL patients. MMC activated with anti-CD3 plus IL-2 killed Daudi significantly less well than IL-2-activated cultures on days 12 and 19 (P = .03); no significant differences were observed in lysis of LAK-resistant Nalm-6 or cryopreserved ALL blast targets. Dose response of anti-CD3 augmentation of Daudi and Nalm-6 killing was different in IL-2-and IL-2+anti-CD% stimulated cultures. In the presence of phytohemagglutinin (PHA), both IL-2-and anti-CDt+IL-2-activated cultures developed lectin-dependent cellular cytotoxicity (LDCC) against LAK-resistant targets. Thus, anti-CD3+IL-2 activation of either PBMC or MMC contributes not only t o significantly increased proliferation, but also generates populations of T cells with high cytolytic potential. Cryopreserved marrow may be an acceptable alternative source of anti-CD3+IL-2-stimulated cells for future immunotherapy protocols in conjunction with marrow transplantation. 0 1992 by The American Society of Hematology.
been particularly successful when both allogeneic cells and interleukin-2 (IL-2) have been used.lO-lz This is also in agreement with generally superior results using IL-2 plus autologous lymphokine-activated killer (LAK) cells against NHL compared with IL-2 alone (0111 at the National Cancer Institute) (NCI)13J4 and IL-2 plus LAK cells after autologous BMT15J6 compared with IL-2 alone. [17] [18] [19] However, obtaining sufficient cells for activation and adoptive cellular therapy in patients after BMT is problematic. Many patients have marked to moderately hypocellular bone marrow and lymphopenia for extended periods of time after marrow transplantation. Additionally, cells obtained after BMT proliferate poorly in response to IL-2, even with anti-CD3 present in the culture.19 Recent protocols at the NCI Biologic Response Modifiers Program (Frederick, MD) have used cells obtained by peripheral blood cytopheresis that are stimulated overnight with anti-CD3 (T-activated killer cells [TAK]), washed, and then transfused into patients receiving IL-2.20 These patients have rapid in vivo expansion of CD3+ lymphoid cells with peakcell counts of 14,000 to 70,00O/~L. In this situation the host not only serves as an "in vivo bioreactor," but also has significant continuous exposure to TAK cells.
Because IL-2-activated marrow has significant antitumor activity in vitro and in vivo21-26 it is possible that not only peripheral cytopheresis but also activated cryopreserved human marrow may be used after BMT. In order to consider an approach in marrow transplant patients, we compared the proliferation and cytolytic function of cellular material obtained from peripheral blood and bone 
MATERIALS AND METHODS
Patient samples. After informed consent, patients with ALL in remission (n = 15) or NHL (n = 7) and normal volunteer donors (n = 8) had marrow aspirated from the posterior iliac crest and blood collected into heparinized syringes. Mononuclear cells were isolated by dilution 1:l in Hanks' Balanced Salt Solution (HBSS) and layering the specimed over Ficoll-Hypaque (Pharmacia, Piscataway, NJ), centrifugation at 1,500g X 25 minutes, then washing of the cells obtained from the interface with RPMI 1640 with 25 mmoliL HEPES buffer, 100 UimL penicillin, 100 FglmL streptomycin, 2 mmol/L L-glutamine (GIBCO, Grand Island, NY) and 5% heat-inactivated pooled human serum. Samples were placed in media at a concentration of lo7 to 5 x 107/mL with 20% human serum and 10% dimethyl sdlfoxide (DMSO) and frozen at a controlled rate to -70°C before storage in liquid nitrogen. Cells were thawed by rapid immersion and gentle agitation of a vial of cells in a 37°C water bath, then washing with media containing 10 kg/mL DNAase (Sigma, St Louis, MO; no. D5025) to prevent clumping, then washing in media without DNAase x 2.
Mononuclear cells were diluted to 5 x lo5 cellslmL in media containing anti-CD3 (OKT3, Ortho, Raritan NJ; 0 to 100 ng/mL for synergy experiments; otherwise 10 ng/mL) and recombinant human IL-2 (Hoffmann La Roche, Nutley, NJ; 0 to 1,000 UimL in synergy experiments, otherwise 100 UlmL). Cells were counted and diluted every 3 to 4 days to 5 x lo5 cells/mL to maintain densities < 2 x lo6 cellslml. Short-term anti-CD3 stimulation was performed by addition of anti-CD3 to the mononuclear cells, then washing in media x 3 at the specified time (1 to 18 hours). Cells were then cultured in media containing IL-2.
Proliferation was estimated by plating 5 X lo4 cells in a volume of 100 WL in triplicate in a 96-well microtiter plate, pulsing with 25 JLL of 1 5 0 dilution of 3H thymidine (1 mCi) (Amersham, Arlington Heights, IL; 0.4 pCi/ well) on specified days. Wells were harvested onto filter paper discs after 6 hours for scintillation counting. Direct cell counts were done to determine fold expansion of each culture.
5'Cr release microcytotoxicity assays were performed in 96-well microtiter plates19 using 500 Wr-labeled tumor targets per well and effector: target ratios of 30:1, lO:l, 3.3:l and 1.1:l by serial threefold dilution of the first row before the addition of radiolabeled targets. Plates were centrifuged 5 minutes at 500 rpm to ensure cell contact, incubated 4 hours at 3 7 T , then cetltrifuged at 1,000 rpm. One hundred microliters of supernatant was harvested into glass scintillation vials before liquid scintillation counting. Malignant target included cell lines W62 (chronic myelogenous leukemia [CML] , natural killer [NKI-sensitive), Daudi (NK-resistant), and Nalm-6 (ALL; LAK-resistant) and cryopreserved LAK-resistant blasts from a B-lineage ALL patient in relapse (GS ALL blasts). In some experiments, W r release cytotoxicity assays were also performed using anti-CD3 (0 to 1,500 ng per well) to activate cytolytic function or PHA-P (Sigma L-9132) at a final concentration of 30 KglmL to assess lectin-dependent cellular cytotoxicity (LDCC).
Fold proliferation and cytotoxicity of individual samples obtained from peripheral blood or marrow and then stimulated with IL-2 or IL-2 plus anti-CD3 were analyzed using descriptive statistics and paired and unpaired t-tests as calculated 
Statistical analysrs.
using Statworks version 1.1 software (Cricket Software, Malvern, PA).
RESULTS

Proliferative capacity of fresh versus cryopreserved marrow.
To assess the proliferative capacity of fresh and cryopreserved marrow, we measured the DNA synthesis and growth rates after short-term stimulation with anti-CD3 +IL-2. In some experiments, proliferation of cryopreserved cells was improved compared with fresh cells. Figure  1 shows a representative experiment in which the 3H thymidine incorporation into DNA as measured following initial overnight anti-CD3 stimulation and 5 days of culture in IL-2. At all concentrations of IL-2 tested cryopreserved marrow had equal or superior 3H thymidine incorporation into DNA.
Time required for stimulation of marrow proliferation by anti-CD3. The time required for effective stimulation of cryopreserved marrow with anti-CD3 is brief. As shown in Fig 2 no difference was observed in cultures stimulated 1,3, and 18 hours with 10 ng/mL anti-CD3 before washing and plating in media containing IL-2 (10 U/mL). However, stimulation without anti-CD3 (ie, with IL-2 only) resulted in only % the levels of proliferation of anti-CD3-stimulated cultures.
Syneigy between IL-2 and anti-CD3 in augmentation of marow proliferation. The presence of both anti-CD3 and IL-2 in cultures of cryopreserved marrow mononuclear cells (MMC) facilitated proliferation in a synergistic and dosedependent manner (Fig 3) . Significant proliferation occurred with IL-2 alone only at concentrations in excess of 3 U/mL. Although all concentrations of anti-CD3 tested markedly augmented proliferation, the most prominent effects of low-dose anti-CD3 activation occurred at concen- trations between 3 and 100 ng/mL; 1.2 ng/mL resulted in an intermediate but significantly inferior proliferation compared with higher concentrations. For example, at 3.7 U of IL-2/mL 3.7 ng of anti-CD3/mL significantly augmented proliferation better than 0.41 ng/mL (P < .001) or 1.2 ng (P = .028); concentrations of anti-CD3 at or above 3.7 ng/mL were not significantly different (eg, 3.7 v 11.1 ng/mL t-testf = .394).
Effect of cell density on activation of MMC with anti-CD3. Figure 4 depicts the effect of cell density on proliferation of anti-CD3 activated MMC. After 18 hours incubation of MMC with 10 ng/mL anti-CD3 before washing and plating cells into culture, significantly superior proliferation was obtained at densities of 2.5 x 106 cells/mL compared with $10, or 20 x 106 cells/mL (t-test P = .001). Similar results were also obtained with 30 ng anti-CD3/mL with optimal 3H thymidine incorporation in the culture activated at a density of 2.5 x 106 cells/mL. Comparison of marrow versus peripheral blood prolifeation. As detailed in Table 1 , the source of mononuclear cells for culture (peripheral blood v marrow) had no effect on the proliferation of B-lineage malignancy patient samples. No significant differences in fold ccll number increases were seen comparing peripheral blood versus marrowderived cultures of 22 patient samples (paired t-test MMC v peripheral blood mononuclear cells [ PBMC] cultured in IL-2 only P = .76, .11, .24 on days 7, 14, 21, respectively; paired t-test MMCversus PBMCcultured in anti-CD3+IL-2 P = .78, .40, and .09 on days 7, 14, and 21, respectively). Also normal control samples, ALL, and NHL patient samples had similar patterns of proliferation. Most rapid proliferation was observed between days 7 and 14 for anti-CD3+IL-2-stimulated cultures. The use of anti-CD3 in addition to IL-2 facilitated 50-to 200-fold higher increases in cell number than IL-2 alone.
Mean fold increases in cell number of B-lineage malignancy patient samples (n = 22) were significantly higher for cultures stimulated with anti-CD3+IL-2 comparcd with IL-2 only (paired t-test of IL-2 v anti-CD3 plus IL-2 patient samples: P = .006, .001, and .01 for PBMC on days 7, 14, and 21, respectively; P = .02, .OS, and .006 for MMC on days 7, 14, and 21, respectively). As shown in Table 2 , Table 3 , the lysis of the ALL target, Nalm-6, by these effectors was in general low. Nalm-6 lysis by day 12 IL-2+anti-CD3-stimulated PBMC (4.6, SE 1.9) was not significantly different than marrow-derived effectors (12.9%, SE 4.6; paired t-test P = .207). Similarily, on day 19 no significant differences in Nalm-6 lysis were observed between IL-2tanti-CD3-stimulated effectors (12.9%, SE 3.6 v 15.3% SE 5.9; paired t-test P = .582). Nevertheless, because the number of cells resulting from anti-CD3+IL-2 activation is 50-to 200-fold more than IL-2 activation, the total cytolytic potential of this scheme is greater than using IL-2 alone.
Functional differences between IL-2 only versus anti-CD3 plus IL-2 stimulation. Differences in cytolytic function of IL-Zactivated cultures and anti-CD3 +IL-2-activated cultures were also studied using two methods to augment lytic activity against hematologic tumor targets. When anti-CD3 was added to the cytolytic assay, increases in the cytotoxicity of the cultures were not only dose-and target-dependent, but also related to the method of activation (Fig 5) . One and 5 ng anti-CD3iwell significantly stimulated day 5
anti-CD3+ IL-2-activated effectors to kill Nalm-6 targets (Fig 5, top; no anti-CD3 v 1 and 5 ng/mL t-test P = .004 and .002, respectively). Daudi targets were increasingly susceptible to lysis by anti-CD3 +IL-2-activated effectors only at much higher concentrations of anti-CD3 (Fig 5, bottom; anti-CD3+IL-2 v IL-2 activation at 500 and 1,500 ng/mL t-test P = .009 and .001, respectively). IL-2-activated effectors had no augmentation of either Nalm-6 or Daudi killing with the addition of anti-CD3. Poor killing of LAKresistant Nalm-6 or cryopreserved ALL blasts by ALL patients after 17 to 20 days of culture was markedly enhanced in lectin-dependent cellular cytotoxicity (LDCC) assay (Table 4) indicating that the "lytic machinery" for the killing of LAK-resistant targets was present in both cultures. On the other hand, the killing of targets already quite susceptible to effector cell-mediated lysis (eg, K562 or Daudi4') or in occasional patient samples (eg, ALL patient ML against Nalm-6 in Table 4 ) was diminished by phytohemagglutinin (PHA).
DISCUSSION
The differences in relapse rates after autologous, syngenic, or t-depleted BMT versus allogeneic BMT suggest that activated T cells in the graft may in some cases effectively eliminate residual leukemia. Nevertheless, because almost half of the patients receiving allogeneic BMT for poor-prognosis ALL also r e l a p~e ,~,~ improved in vivo preparative regimens are needed to significantly lower relapse rate. The use of IL-2 in vitro and in vivo has been investigated as a means to amplify a graft-versus-leukemia effect and/or induce LAK activity in marrow against malignan~y.*l-~~ Studies with NK cell-resistant dissemi- post-BMT therapy might use autologous adoptive killer cells from cryopreserved marrow samples obtained before BMT. Therefore, our study sought to compare proliferation and antileukemia cytolytic activity of IL-Zactivated cells from marrow vcrsus peripheral blood. Similar proliferation was observed using cellular material from marrow compared with blood with either IL-2-activation or anti-CD3 plus IL-2-activation schemes. Proliferative capacity was significantly increased using the anti-CD3+ IL-Zactivation scheme compared with IL-2 alone (P < .01 for all comparisons, Table 1 ).
Because in vitro cytotoxicity against hematopoietic tumor
For personal use only. on June 6, 2017. by guest www.bloodjournal.org From targets may reflect the in vivo lytic potential, cytotoxicity of IL-2-and anti-CD3 +IL-2-activated effectors were tested against K562 (NK-sensitive), Daudi (NK-resistant, LAKsensitive), and Nalm-6 (NK-and LAK-resistant) and cryopreserved GS B-lineage ALL blasts (NK-and LAKresistant). Patterns of cytotoxicity including studies with anti-CD3 or PHA in the assay indicate that the IL-2-and the anti-CD3+IL-Zactivated cultures can have substantial biologic differences in patterns of tumor target lysis. Increased cytotoxicity against the LAK-resistant GS ALL blasts and Nalm-6 in the LDCC assay (Table 4) may be caused by stabilization of effector:target interaction by PHA; on the other hand, decreased cytotoxicity of the more easily killed targets K562 and Daudi in the presence of PHA may be a function of difficulty in recycling and repetitive killing by lymphoid effector cells. Studies by Stohl et alZ7 previously demonstrated that anti-CD3 augmentation of cytolytic activity against Daudi targets has IL-2-dependent and IL-2-independent components. In our study, in the presence of IL-2, different patterns of dosedependent augmentation of killing of Daudi and Nalm-6 by anti-CD3 could be observed (Fig 5) . These data may indicate that initial stimulation of these cultures with anti-CD3 in the presence of IL-2 can possibly induce a differential capacity for subsequent signaling through the TCRICD3 complex than culture in IL-2 only. Phenotypic analysis of surface CD54 by fluorescenceactivated cell sorter (FACS) demonstrated that not only K562 and Daudi have high expression of CD54 as previously reported,28 but also that Nalm-6 had a high density of this target ligand for CDllalCD18 (P.M.A., D.H., July 1991, data not shown). Nevertheless, killing of Nalm-6 was difficult using either IL-2-or anti-CD3+IL-2-activated cultures. It is possible that B-lineage malignancy cells in vivo may be more analogous to killing of Nalm-6 or cryopreserved autologous ALL blasts (Table 4 ) than K562 or Daudi cytolysis. Because LDCC uses PHA-P in the assay essentially to provide a molecular ''glue'' between effectors and targets via stable binding of oligosaccharides, the LDCC assay provides an estimate of killing potential regardless of adhesion molecules that were involved in the absence of lectin. Approaches that can potentially bind targets and effectors together in vivo, such as the use of heterofunctional a n t i b o d i e~~~-~~ or fusion proteins between antibodies and tumor or T-cell-binding ligands, may be analogous to the LDCC assay. If so, the efficacy of anti-CD3 +IL-2-activated cells may be enhanced using bispecific antibodies or fusion proteins.
The use of anti-CD3 in combination with IL-2 has been previously shown to lead to very rapid expansion of activated cell numbers using murine ~plenocytes,3~-~~ and human PBMC. 40-4z Recently it has been shown in a murine model system that in vivo antitumor effectiveness is mediated by CDS-positive cells in collaboration with CD4-positive cells.43 Furthermore, IL-2-activated marrow with IL-2 after BMT in a murine AML model increased survival compared with BMT or BMT+IL-2. 44 In view of the former and the potential of brief in vitro anti-CD3 activation followed by in vivo IL-2 administration to yield activated T cells to mediate a graft-versus-leukemia effect, we have examined the potential of cryopreserved marrow cells to respond to anti-CD3-cIL-2 activation. In a manner similar to b l o~d ,~* -~~ cryopreserved marrow-derived mononuclear cells responded to IL-2+anti-CD3 with both enhanced proliferation in a dose-dependent synergistic manner and the development of cytotoxicity against hematologic malignancies. Thus, not only IL-2 but also anti-CD3+IL-2 activation strategies may be useful adjuncts to current radiation and chemotherapy preparative BMT regimens in the treatment of resistant hematologic malignancy.
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